This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) COVID Pill Ineffective in Standard Risk Patients
by Zacks Equity Research
Pfizer (PFE) stops enrolling patients in a phase II/III study evaluating its COVID pill in standard-risk population after new data from this study showed that it is not all statistically significant.
Merck (MRK) Keytruda Adjuvant Lung Cancer sBLA Accepted by FDA
by Zacks Equity Research
The FDA is expected to give its decision on Merck's (MRK) Keytruda sBLA for adjuvant stage IB-IIIA NSCLC, following complete surgical resection, on Jan 29, 2023.
Bristol Myers (BMY) Up 20.4% YTD: Will the Momentum Continue?
by Zacks Equity Research
Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.
Merck (MRK) Stock Moves -1.65%: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $88, moving -1.65% from the previous trading session.
Roche (RHHBY) Gets EU Nod for Lunsumio, Tecentriq Label Expansion
by Zacks Equity Research
Roche (RHHBY) obtains EU approval for Lunsumio for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) and label expansion of Tecentriq.
Bristol Myers (BMY) to Acquire Turning Point, Withdraws sBLA
by Zacks Equity Research
Bristol Myers (BMY) is set to acquire Turning Point to bolster its oncology portfolio. The company also withdraws its sbLA for Reblozyl.
Merck (MRK) Stock Moves -0.1%: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $89.91, marking a -0.1% move from the previous day.
Regeneron (REGN) to Buy Sanofi's Stake in Libtayo, Stock Down
by Zacks Equity Research
Regeneron (REGN) will obtain global rights to Libtayo from Sanofi in exchange for an upfront payment of $900 million and royalties.
The Zacks Analyst Blog Highlights AstraZeneca, Merck, Roche, J&J, and Pfizer
by Zacks Equity Research
AstraZeneca, Merck, Roche, J&J, and Pfizer are part of Zacks top Analyst Blog
Bristol Myers' (BMY) Opdivo Combos Get FDA Nod for ESCC
by Zacks Equity Research
Bristol Myers (BMY) secures an FDA approval for two Opdivo-based regimens as the first-line treatment of unresectable advanced or metastatic esophageal squamous cell carcinoma.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Iovance (IOVA) Down After Announcing Data From Melanoma Study
by Zacks Equity Research
Results from a cohort of the phase II study evaluating Iovance's (IOVA) melanoma candidate were not as superior as data from another cohort of the same study.
Mirati (MRTX) Down 23% on Mixed Data From Lung Cancer Study
by Zacks Equity Research
Mirati (MRTX) posts positive data from a phase II study evaluating its lung cancer candidate adagrasib. However, the drug caused side-effects in a large number of study participants.
Exelixis (EXEL) Announces Results From Phase II HNSCC Study
by Zacks Equity Research
Exelixis (EXEL) phase II study evaluating Cabometyx in combination with Keytruda in patients with recurrent or metastatic head and neck squamous cell carcinoma meets primary goal.
Pharma Stock Roundup: EU Nod for AZN, JNJ & Others, PFE COVID Jab Effective in Kids
by Kinjel Shah
European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.
Merck (MRK) Keytruda Gets EU Nod for Expanded Breast Cancer Use
by Zacks Equity Research
The European Commission approves Merck's (MRK) Keytruda for high-risk early-stage TNBC, which expands its eligible patient population.
Seagen (SGEN) Posts Positive Data from New Study on Tukysa
by Zacks Equity Research
Seagen (SGEN) reports favorable data on the pivotal phase II MOUNTAINEER study evaluating Tukysa in combination with Herceptin for treating HER2-positive metastatic colorectal cancer.
Merck's (MRK) Keytruda Gets CHMP Nod for Expanded Melanoma Use
by Zacks Equity Research
Merck's (MRK) anti-PD-1 therapy Keytruda nears potential approval as an adjuvant treatment for adolescent pediatric patients with stage IIB, IIC or III melanoma following complete resection.
Mirati (MRTX) Seeks EU Nod for Adagrasib to Treat Lung Cancer
by Zacks Equity Research
Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck, and Glaxo
by Zacks Equity Research
Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.
4 Large Drug Stocks to Watch as the Industry Recovers
by Kinjel Shah
Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.
Merck (MRK) Outperforms Industry This Year So Far: Here's Why
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.
Pfizer (PFE) Gets EUA for Use of Comirnaty Booster in Children
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech gets authorization for emergency use of booster dose of its COVID-19 vaccine, Comirnaty, in children aged between 5 years and 11 years.
Bristol Myers (BMY) Phase III CheckMate -901 Study Disappoints
by Zacks Equity Research
Bristol Myers (BMY) phase III CheckMate -901 study fails to meet the primary endpoint of overall survival in patients with untreated unresectable or metastatic urothelial cancer.
Exelixis (EXEL) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure.